Intrathecal Drug Delivery System for Refractory Pancreatic Cancer Pain
Rationale for IDDS Selection
- The European Society for Medical Oncology (ESMO) guidelines recommend considering intrathecal administration when patients have inadequate pain relief despite systemic opioid escalating doses, non-effective response to switching the opioid or route of administration, and life expectancy >6 months 1
Why Other Options Have Been Exhausted
- Celiac plexus neurolysis typically provides effective palliation in approximately 70% of patients, with pain relief lasting 3-6 months, but this has already failed in this case 2, 1
- Radiation therapy for pancreatic pain typically provides temporary relief in 40-80% of patients, but has been ineffective in this case 2
IDDS Technical Approach
- Intrathecal administration has the advantage of being less affected by the presence of extensive epidural metastasis, and the drugs most commonly used are morphine, ziconotide, baclofen, local anesthetics, and subanesthetic doses of ketamine 1
Implementation Strategy
- A trial using a temporary epidural or spinal catheter must be performed before implanting a permanent pump to assess efficacy, optimal drug combination and dosing, patient tolerance, and side effects 1, 3
Critical Caveats
- Intraspinal techniques should be included as part of cancer pain management strategy, but widespread use should be avoided, and referral to an interventional pain specialist or anesthesiologist experienced in IDDS is mandatory 1, 3